Ocular Therapeutix (OCUL) Accumulated Depreciation & Amortization (2013 - 2025)

Ocular Therapeutix has reported Accumulated Depreciation & Amortization for 13 years, with the latest figure at $27.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 16.45% year-over-year to $27.5 million; the trailing twelve-month figure through Dec 2025 stood at $27.5 million (up 16.45% YoY), and the FY2025 full-year result was $27.5 million, up 16.45% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $27.5 million, up from $23.6 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $27.5 million in Q4 2025, with the low at $15.2 million in Q4 2021.
• Average Accumulated Depreciation & Amortization over 5 years is $20.8 million, with a median of $20.3 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization rose 18.93% in 2021 and increased 13.62% in 2022.
• Tracing OCUL's Accumulated Depreciation & Amortization over 5 years: stood at $15.2 million in 2021, then grew by 13.62% to $17.3 million in 2022, then gained by 17.26% to $20.3 million in 2023, then gained by 16.64% to $23.6 million in 2024, then gained by 16.45% to $27.5 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $27.5 million (Q4 2025), $23.6 million (Q4 2024), and $20.3 million (Q4 2023), per Business Quant data.

Peer Comparison